<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        168-186-02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CLAMYCIN 250 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLARITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        38.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each <strong>Clamycin</strong> tablet contains 250mg or 500mg of the active ingredient clarithromycin. <strong>Clamycin</strong> belongs to a group of medicines called macrolide antibiotics. Antibiotics stop the growth of bacteria (bugs) which cause infections.</p><p><strong>Clamycin</strong> tablets are used to treat infections such as:</p><p>1. Chest infections such as bronchitis and pneumonia</p><p>2. Throat and sinus infections</p><p>3. Skin and soft tissue infections such as cellulitis, folliculitis or erysipelas</p><p>4. Infections caused by certain types of bacteria called Mycobacteriae</p><p>5. <em>Helicobacter pylori </em>infection associated with duodenal ulcer</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Clamycin if: </strong></p><p>&bull;&nbsp; you know that you are <strong>allergic </strong>to clarithromycin, other macrolide antibiotics such as erythromycin or azithromycin, or any of the other ingredients in the tablets.</p><p>&bull;&nbsp; you are taking medicines called ergotamine or dihydroergotamine tablets or use ergotamine inhalers for migraine. Consult your doctor for advice on alternative medicines.</p><p>&bull;&nbsp; you are taking medicines called simvastatin, lovastatin, atorvastatin or rosuvastatin (used to lower increased blood fats such as cholesterol and triglycerides).</p><p>&bull;&nbsp; you are taking medicines called terfenadine or astemizole (for hay fever or allergies) or cisapride or pimozide tablets as combining these drugs can sometimes cause serious disturbances in heart rhythm. Consult your doctor for advice on alternative medicines.</p><p>&bull;&nbsp; you are taking a medicine called colchicine and are being treated for kidney or liver problems.</p><p>&bull;&nbsp; you have abnormally low levels of potassium in your blood (hypokalaemia)</p><p>&bull;&nbsp; you have any liver and/or kidney problems</p><p>&bull;&nbsp; you or someone in your family has a history of heart rhythm disorders (ventricular cardiac arrhythmia, including torsades de pointes) or abnormality of electrocardiogram (ECG, electrical recording of the heart) called &ldquo;long QT syndrome&rdquo;</p><p><strong>Clamycin is not suitable for use in children under 12 years of age. </strong></p><p><strong>Take special care with Clamycin; </strong></p><p>&bull;&nbsp; if you have heart problems</p><p>&bull;&nbsp; if you are pregnant or breast feeding</p><p>&bull;&nbsp; if you have myasthenia gravis (a disorder which causes muscle weakness)</p><p>&bull;&nbsp; if you are already taking colchicine (for the treatment of gout) as this can cause serious side effects</p><p>If any of these apply to you, consult your doctor before taking <strong>Clamycin</strong>.</p><p>If you develop severe or prolonged diarrhoea during or after receiving <strong>Clamycin</strong>, tell your doctor <strong>immediately</strong>, as this could be a symptom of more serious conditions such as pseudomembranous colitis or clostridium difficile associated diarrhoea.</p><p>If you develop any symptoms of liver dysfunction such as anorexia (loss of appetite), yellowing of the skin or whites of the eyes, dark urine, itching or tender abdomen, stop taking <strong>Clamycin</strong> and tell your doctor <strong>immediately. </strong></p><p>Long term use of <strong>Clamycin</strong> may lead to infection with resistant bacteria and fungi.</p><p><strong>Taking other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking, or have recently taken, any other medicines, including those obtained without a prescription.</p><p>This is especially important if you are taking medicines called;</p><p>&bull;&nbsp; Digoxin, quinidine or disopyramide (used to treat heart problems). Your heart may need to be monitored (ECG test) or you may need to have blood tests if you take clarithromycin with some medicines used to treat heart problems</p><p>&bull;&nbsp; Warfarin, or any other anticoagulant (used to thin your blood). It may be necessary to have blood tests to check that your blood is clotting efficiently</p><p>&bull;&nbsp; Omeprazole (used for the treatment of indigestion and stomach ulcers) unless your doctor has prescribed it for you to treat Helicobacter pylori infection associated with duodenal ulcer</p><p>&bull;&nbsp; Ergotamine or dihydroergotamine (for the treatment of migraine)</p><p>&bull;&nbsp; Colchicine (for the treatment of gout). Your doctor may wish to monitor you</p><p>&bull;&nbsp; Theophylline (used in patients with breathing difficulties such as asthma)</p><p>&bull;&nbsp; Terfenadine or astemizole (for hay fever or allergy)</p><p>&bull;&nbsp; Triazolam, alprazolam or midazolam (sedatives)</p><p>&bull;&nbsp; Cilostazol (for poor circulation)</p><p>&bull;&nbsp; Cisapride or cimetidine (for stomach disorders)</p><p>&bull;&nbsp; Carbamazepine, valproate, phenytoin or phenobarbital (for the treatment of epilepsy)</p><p>&bull;&nbsp; Methylprednisolone (a corticosteroid)</p><p>&bull;&nbsp; Vinblastine (for treatment of cancer)</p><p>&bull;&nbsp; Ciclosporin, tacrolimus or sirolimus (immune suppressants used for organ transplants and severe eczema)</p><p>&bull;&nbsp; Pimozide or St. John&rsquo;s wort (for mental health problems)</p><p>&bull;&nbsp; Rifabutin, rifampicin, rifapentine, fluconazole and itraconazole (treatments for infectious diseases)􀀀</p><p>&bull;&nbsp; verapamil (for high blood pressure)</p><p>&bull;&nbsp; Tolterodine (for overactive bladder)</p><p>&bull;&nbsp; Simvastatin and lovastatin (known as HMG-CoA reductase inhibitors for the treatment of high cholesterol)</p><p>&bull;&nbsp; Ritonavir, efavirenz, nevirapine, atazanavir, saquinavir, etravirine and zidovudine(anti-viral or anti-HIV drugs)</p><p>&bull;&nbsp; Sildenafil, vardenafil and tadalafil (for impotence in adult males or for use in pulmonary arterial hypertension - high blood pressure in the blood vessels of the lung)</p><p>&bull;&nbsp; Insulin, rosiglitazone, repaglinide, pioglitazone or nateglinide (medicines for the treatment of diabetes)</p><p>&bull;&nbsp; Aminoglycosides (a type of antibiotic) such as gentamycin, streptomycin, tobramycin, amikacin, netilmicin</p><p><strong>Pregnancy and Breast-feeding </strong></p><p>If you are pregnant, think you may be pregnant, or if you are breast-feeding, consult your doctor before taking <strong>Clamycin</strong> tablets as their safety in pregnancy and breast-feeding is not known.</p><p><strong>Driving and operating machinery </strong></p><p><strong>Clamycin</strong> may cause dizziness, vertigo, confusion and disorientation. If you are affected do not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <strong>Clamycin</strong> tablets exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The usual dose is;</p><p><strong>For chest infections, throat or sinus infections and skin and soft tissue infections: </strong></p><p>The usual dose for adults and children over 12 years is 250mg twice daily for seven days, e.g. one <strong>Clamycin</strong> 250mg tablet in the morning and one in the early evening. Your doctor may increase the dose to one <strong>Clamycin</strong> 500mg tablet twice daily in severe infections.</p><p><strong>Clamycin</strong> tablets should be swallowed with at least half a glass of water.</p><p>Do not give these tablets to children under 12 years. Your child&#39;s doctor will prescribe another suitable medicine for your child.</p><p><strong>For the treatment of infections caused by certain types of bacteria called Mycobacteria </strong></p><p>For treatment of such infections, the usual dose is 500mg twice daily. Your doctor may increase the dose to 1000mg twice daily if no response is seen to the lower dose after 3 - 4 weeks.</p><p>For the prevention of mycobacteria infections, the usual dose in adults is 500mg twice daily.</p><p><strong>For the treatment of <em>Helicobacter pylori </em>infection associated with duodenal ulcers: </strong></p><p>There are a number of effective treatment combinations available to treat <em>Helicobacter pylori </em>in which <strong>Clamycin</strong> tablets are taken together with one or two other drugs.</p><p>These combinations include the following:</p><p>a) One <strong>Clamycin</strong> 500mg tablet taken twice a day together with amoxycillin 1000mg taken twice a day with a proton pump inhibitor at the recommended daily dose for 7 days (7 day Triple Therapy).</p><p>b) One <strong>Clamycin</strong> 500mg tablet taken twice a day together with a proton pump inhibitor at the recommended daily dose plus metronidazole 400mg taken twice a day for 7 days (7 day Triple Therapy).</p><p>c) One <strong>Clamycin</strong> 500mg tablet taken twice a day together with amoxicillin 1000mg taken twice a day plus omeprazole, 20mg taken once a day for 7-10 days (7-10 day Triple Therapy).</p><p>d) One <strong>Clamycin</strong> 500mg tablet taken three times a day for 14 days together with omeprazole 40mg taken once a day<br />(14 day Dual Therapy).</p><p>The treatment combination which you receive may differ slightly from the above. Your doctor will decide which treatment combination is the most suitable for you. If you are unsure which tablets you should be taking or how long you should be taking them for, please consult your doctor for advice.</p><p><strong>If you take more Clamycin than you should </strong></p><p>If you accidentally take more tablets in one day than your doctor has told you to, or if a child accidentally swallows some tablets, contact your doctor or nearest hospital emergency department immediately. An overdose of <strong>Clamycin</strong> is likely to cause vomiting and stomach pains.</p><p><strong>If you forget to take Clamycin </strong></p><p>If you forget to take a dose of your tablets, take one as soon as you remember. Do not take more tablets in one day than your doctor has told you to.</p><p>Do not stop taking your tablets, even if you feel better. It is important to take the tablets for as long as the doctor has told you to, otherwise the problem might come back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Clamycin</strong> can cause side effects although not everybody gets them.</p><p>If you develop severe or prolonged diarrhoea, which may have blood or mucus in it, during or after taking <strong>Clamycin</strong>, consult your doctor immediately, as these could be symptoms of more serious conditions such as pseudomembranous colitis or clostridium difficile associated diarrhoea. Diarrhoea may occur over two months after treatment with clarithromycin.</p><p>If you develop a rash, difficulty breathing, fainting or swelling of the face and throat, contact your doctor immediately as these may be signs of an allergic reaction and may need emergency treatment.</p><p>If you develop loss of appetite, yellowing of the skin (jaundice), dark urine, itching or tenderness in the abdomen, contact your doctor immediately as these may be signs of liver failure.</p><p>Other side effects may include:</p><p><strong>Common </strong>(affects 1 to 10 users in 100):</p><p>&bull;&nbsp; difficulty sleeping (insomnia)</p><p>&bull;&nbsp; changes in sense of taste</p><p>&bull;&nbsp; headache</p><p>&bull;&nbsp; stomach problems such as feeling sick, vomiting, stomach pain, indigestion, diarrhoea</p><p>&bull;&nbsp; abnormal liver function blood tests</p><p>&bull;&nbsp; rash, excessive sweating, flushing</p><p><strong>Uncommon </strong>(affects 1 to 10 users in 1000):</p><p>&bull;&nbsp; infections of the skin or vagina, yeast infections (thrush)</p><p>&bull;&nbsp; change in the level of white blood cells in the blood (which can make infections more likely)</p><p>&bull;&nbsp; change in the levels of blood platelets in the blood (increased risk of bruising, bleeding or blood clots)</p><p>&bull;&nbsp; allergic reaction</p><p>&bull;&nbsp; decreased appetite</p><p>&bull;&nbsp; anxiety, nervousness, screaming</p><p>&bull;&nbsp; fainting, dizziness, drowsiness, tremor, involuntary movements of the tongue, face, lips or limbs</p><p>&bull;&nbsp; spinning sensation (vertigo), ringing in the ears, hearing loss</p><p>&bull;&nbsp; fast, pounding heart (palpitations), changes in heart rhythm or heart stopping</p><p>&bull;&nbsp; breathing problems (asthma), nosebleed</p><p>&bull;&nbsp; blood clot in the lungs</p><p>&bull;&nbsp; stomach problems such as bloating, constipation, wind (flatulence), belching, heartburn or anal pain,</p><p>&bull;&nbsp; inflammation of the lining of the stomach or oesophagus (the tube connecting your mouth with your stomach)</p><p>&bull;&nbsp; sore mouth, dry mouth, inflammation of the tongue</p><p>&bull;&nbsp; liver problems such as hepatitis or cholestasis which may cause yellowing of the skin (jaundice), pale stools or dark urine</p><p>&bull;&nbsp; increase in liver enzymes</p><p>&bull;&nbsp; itching, hives, inflammation of the skin</p><p>&bull;&nbsp; stiffness, aches or spasms in the muscles</p><p>&bull;&nbsp; kidney problems such as raised levels of protein normally excreted by the kidneys or raised levels of kidney enzymes</p><p>&bull;&nbsp; fever, chills, weakness, fatigue, chest pain or general feeling of discomfort</p><p>&bull;&nbsp; abnormal blood test results</p><p><strong>Not known </strong>(frequency cannot be estimated from available data):</p><p>&bull;&nbsp; infection of the colon</p><p>&bull;&nbsp; infection of the skin or skin folds</p><p>&bull;&nbsp; low blood sugar levels which may cause fainting</p><p>&bull;&nbsp; psychotic disorder, confusion, change in sense of reality, depression, loss of bearings (disorientation), hallucinations (seeing things), abnormal dreams (nightmares).</p><p>&bull;&nbsp; convulsions</p><p>&bull;&nbsp; changes or loss in sense of taste and/or smell</p><p>&bull;&nbsp; paraesthesia (tingling and burning sensation in the skin, numbness, &lsquo;pins and neddles&rsquo; sensation)</p><p>&bull;&nbsp; deafness</p><p>&bull;&nbsp; bleeding</p><p>&bull;&nbsp; inflammation of the pancreas</p><p>&bull;&nbsp; discoloration of the tongue, tooth discolouration</p><p>&bull;&nbsp; liver failure, jaundice (yellowing of the skin)</p><p>&bull;&nbsp; rare allergic skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis (which cause severe illness with ulceration of the mouth, lips and skin), DRESS (which causes severe illness with rash, fever and inflammation of internal organs) or Henoch-Schonlein purpura (which causes purple spots on the skin, joint pain, gastrointestinal and kidney problems)</p><p>&bull;&nbsp; acne</p><p>&bull;&nbsp; muscle disease (myopathy), breakdown of muscle tissue (rhabdomyolysis)</p><p>&bull;&nbsp; inflammation of the kidney (which can cause swollen ankles or high blood pressure) or kidney failure</p><p>There have also been reports that clarithromycin may worsen the symptoms of myasthenia gravis (a condition in which the muscles become weak and tired easily) in patients who already suffer from this condition.</p><p><strong>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</strong></p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effect(s): </u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax: </strong>+966-11-205-7662</p><p><strong>Call NPC at </strong>+966-11-2038222<strong>, Exts: </strong>2317-2356-2353-2354-2334-2340<strong>.</strong></p><p><strong>Toll free phone: </strong>8002490000</p><p><strong>E-mail: </strong>npc.drug@sfda.gov.sa</p><p><strong>Website: </strong>www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp; Do not take <strong>Clamycin </strong>after their use-by (expiry) date which is printed on the box and indented on the blister. The expiry date refers to the last day of the month.</p><p>-&nbsp; Store below 30&deg;C.</p><p>-&nbsp; Do not take <strong>Clamycin </strong>if you notice any visible sign of deterioration.</p><p>-&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredient is clarithromycin. Each tablet contains 250mg or 500mg of clarithromycin.</p><p>The other ingredients are;<em> </em>microcrystalline cellulose, croscarmellose sodium, povidone, polysorbate, starch, magnesium stearate, talc, stearic acid, aerosol, hypermellose, polyethylene glycol, titanium dioxide and D&amp;C yellow No.10 lake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Clamycin film-coated tablets are available in packs containing 14 tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
23/01/2017

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي كل قرص من <strong>كلامايسين</strong> على 250 ملغم أو 500 ملغم من الكلاريثروميسين. ينتمي <strong>كلامايسين</strong> إلى مجموعة من الأدوية التي تعرف باسم المضادات الحيوية من مجموعة الماكرولايدات. تعمل المضادات الحيوية على إيقاف نمو البكتيريا التي تسبب الإصابة بالعدوى.</p><p>تستخدم أقراص <strong>كلامايسين</strong> لعلاج حالات العدوى مثل:</p><p>&bull;&nbsp;&nbsp;&nbsp; عدوى الصدر بالمثل التهاب الشعب الهوائية والالتهاب الرئوي.</p><p>&bull;&nbsp;&nbsp;&nbsp; عدوى الحنجرة والجيوب الأنفية.</p><p>&bull;&nbsp;&nbsp;&nbsp; عدوى الجلد والأنسجة الرخوة بالمثل التهاب النسيج الخلوي، التهاب الجريبات أو الحمرة.</p><p>&bull;&nbsp;&nbsp;&nbsp; العدوى التي تسببها أنواع معينة من البكتيريا تعرف باسم مايكوبكتيريا .</p><p>&bull;&nbsp;&nbsp;&nbsp; عدوى هيليكوباكتر بيلوري المرتبطة مع الإصابة بقرحة الاثني عشر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب عدم تناول <strong>كلامايسين</strong> في الحالات التالية:</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تعلم بأنك تعاني من الحساسية تجاه كلاريثروميسين، والمضادات الحيوية الأخرى من مجموعة الماكرولايدات بالمثل الإريثروميسين</p><p>&bull;&nbsp;&nbsp;&nbsp; أو الأزيثروميسين، أو تجاه أي من المكونات الأخرى في هذه الأقراص.</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أحد الأدوية التي تعرف باسم الإرغوتامين أو ثنائي هيدرو الإرغوتامين على هيئة أقراص أو تستخدم الإرغوتامين بالاستنشاق لحالات الصداع النصفي. استشر طبيبك للحصول على المشورة حول إمكانية استخدام أية أدوية بديلة.</p><p>&bull;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول أحد الأدوية التي تعرف باسم سيمفاستاتين، لوفاستاتين، أتورفاستاتين، روزوفاستاتين (أدوية تستخدم لخفض ارتفاع مستوى الدهون في الدم بالمثل الكوليسترول والدهون الثلاثية).</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أحد الأدوية التي تعرف باسم تيرفينادين أو استيمايزول (لعلاج حمى القش أو الحساسية) أو سيسابريد أو أقراص بيموزيد حيث أن تناول هذه الأدوية في نفس الوقت قد يتسبب أحياناً في حدوث اضطرابات خطيرة في ضربات القلب. استشر طبيبك للحصول على المشورة حول إمكانية استخدام أية أدوية بديلة.</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تتناول دواء يعرف باسم الكولشيسين و تخضع للعلاج من أمراض في الكلى أو في الكبد .</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت&nbsp; تعاني من انخفاض مستويات بوتاسيوم الدم بصورة غير طبيعية (نقص بوتاسيوم الدم)</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أية مشاكل في الكبد و / أو الكلى</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كان لديك أو أحد أفراد العائلة تاريخ مرضي من الإصابة باضطرابات ضربات القلب (عدم انتظام ضربات القلب البطينية، بما في ذلك حالة تورساد دي بوينت) أو اضطراب رسم مخطط كهربية القلب (أي سي جي ، تسجيل كهربائية القلب) وهي ما تعرف باسم &quot;متلازمة طول الزمن الفاصل بين موجات كيو تي &quot;</p><p><strong>لا تناسب أقراص كلامايسين الاستخدام من قبل الأطفال الذين تقل أعمارهم عن 12 سنة.&nbsp; </strong></p><p><strong>يجب توخي الحذر قبل استخدام كلامايسين في الحالات التالية: </strong></p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في القلب</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت حاملاً أو مرضعة</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من داء الوهن العضلي الوبيل (اضطراب يسبب ضعف العضلات) .</p><p>&bull;&nbsp;&nbsp;&nbsp; إذا كنت تتناول في الوقت الحالي دواء كولشيسين (يستخدم لعلاج النقرس) حيث أن هذا قد يتسبب في حدوث تأثيرات جانبية خطيرة .</p><p>إذا كنت تعتقد بأن أي من هذه الحالات تنطبق عليك، استشر طبيبك أو الصيدلي الذي تتعامل معه قبل تناول<strong> </strong><strong>كلامايسين</strong>.</p><p>في حال تعرضك للإصابة بإسهال شديد أو لفترة زمنية طويلة أثناء تناولك <strong>كلامايسين</strong> أو بعد انتهاء العلاج، استشر طبيبك على الفور حيث أن هذه الأعراض قد تكون إشارة إلى وجود ظروف صحية أكثر خطورة بالمثل التهاب القولون الغشائي الكاذب أو الإسهال المرتبط حدوثه بالإصابة بكلوستيريديم ديفيسيل.</p><p>في حال ظهور أية أعراض تدل على وجود قصور وظائف الكبد بالمثل فقدان الشهية، اصفرار الجلد أو بياض العينين، بول داكن اللون، حكة، وترقق منطقة البطن، توقف عن تناول <strong>كلامايسين</strong> واخبر طبيبك على الفور.</p><p>قد يؤدي استخدام <strong>كلامايسين</strong> لفترات طويلة إلى حدوث عدوى نتيجة الإصابة بأحد أنواع البكتيريا أو الفطريات المقاومة له.</p><p><strong>تناول الأدوية الأخرى </strong></p><p>يرجى أن تخبر طبيبك أو الصيدلي الذي تتعامل معه إذا كنت تتناول أو تناولت مؤخراً أية أدوية أخرى، بما في ذلك الأدوية التي تصرف بدون وصفة طبية.</p><p>من المهم أخذ مايلي بعين الاعتبار إذا كنت تتناول أحد الأدوية التالية:</p><p>&bull;&nbsp;&nbsp;&nbsp; الديجوكسين، كينيدين أو ديسوبيراميد (تستخدم لعلاج مشاكل في القلب). قد يحتاج القلب في هذه الحالة إلى الخضوع للمراقبة (بواسطة فحص أي سي جي)&nbsp; أو قد تكون بحاجة إلى إجراء فحوصات للدم إذا كنت تتناول كلاريثروميسين مع أحد الأدوية المستخدمة لعلاج مشكلات القلب .</p><p>&bull;&nbsp;&nbsp;&nbsp; الوارفارين أو أي من مضادات التخثر الأخرى (تستخدم لتمييع الدم). قد يتطلب الأمر إجراء فحوصات للدم للتأكد من أن آلية تخثر الدم لديك جيدة</p><p>&bull;&nbsp;&nbsp;&nbsp; أوميبرازول ( يستخدم لعلاج عسر الهضم أو قرحة المعدة) ما لم يصفها&nbsp; لك الطبيب لعلاج العدوى بهيليكوباكتر بيلوري المرتبطة بحدوث قرحة الاثني عشر</p><p>&bull;&nbsp;&nbsp;&nbsp; الإرغوتامين أو ثنائي هيدروأرغوتامين (لعلاج الصداع النصفي)</p><p>&bull;&nbsp;&nbsp;&nbsp; الكولشيسين (لعلاج النقرس). قد يرغب طبيبك بوضعك تحت المراقبة</p><p>&bull;&nbsp;&nbsp;&nbsp; الثيوفيلين (يستخدم للمرضى الذين يعانون من صعوبات في التنفس بالمثل الربو)</p><p>&bull;&nbsp;&nbsp;&nbsp; تيرفينادين أو استيمايزول (لحمى القش أو الحساسية)</p><p>&bull;&nbsp;&nbsp;&nbsp; تريازولام، ألبرازولام أو ميدازولام (مهدئات)</p><p>&bull;&nbsp;&nbsp;&nbsp; كوليستازول (لضعف الدورة الدموية)</p><p>&bull;&nbsp;&nbsp;&nbsp; سيسابريد أو سيميتيدين (لاضطرابات المعدة)</p><p>&bull;&nbsp;&nbsp;&nbsp; كاربامازيبين، فالبروات، الفينيتوين أو الفينوباربيتال (لعلاج الصرع)</p><p>&bull;&nbsp;&nbsp;&nbsp; ميثيل البريدنيزولون (كورتيكوستيرويد)</p><p>&bull;&nbsp;&nbsp;&nbsp; فينبلاستين (لعلاج السرطان)</p><p>&bull;&nbsp;&nbsp;&nbsp; سيكلوسبورين، تاكروليموس أو سيروليمس (مثبطات المناعة المستخدمة في عمليات زرع الأعضاء وحالات الاكزيما الشديدة)</p><p>&bull;&nbsp;&nbsp;&nbsp; بيموزيد أو نبتة سانت جون (لمشكلات الصحة العقلية)</p><p>&bull;&nbsp;&nbsp;&nbsp; ريفابوتين، ريفامبيسين، ريفابنتين، فلوكونازول وايتراكونازول (لعلاج الأمراض المعدية)</p><p>&bull;&nbsp;&nbsp;&nbsp; فيراباميل (لارتفاع ضغط الدم)</p><p>&bull;&nbsp;&nbsp;&nbsp; تولتيرودين (لفرط نشاط المثانة)</p><p>&bull;&nbsp;&nbsp;&nbsp; سيمفاستاتين ولوفاستاتين (المعروفة باسم مثبطات الإنزيم المختزل اتش ام جي - سي او أي ) لعلاج ارتفاع الكوليسترول في الدم.</p><p>&bull;&nbsp;&nbsp;&nbsp; ريتونافير، ايفافيرنز، نيفيرابين، اتازانافير، ساكوينافير، ايترافايرين وزيدوفودين (مضادات الفيروسات، أو مضادات فيروس نقص المناعة البشرية)</p><p>&bull;&nbsp;&nbsp;&nbsp; سيلدينافيل، فاردينافيل و تادالافيل (تستخدم لحالات العجز الجنسي لدى الذكور البالغين أو لارتفاع ضغط الدم الشرياني الرئوي &ndash; ارتفاع ضغط الدم في الأوعية الدموية المتواجدة في الرئة)</p><p>&bull;&nbsp;&nbsp;&nbsp; الأنسولين، روزيجليتازون، ريباجلانايد، بيوجليتازون أو نيتيجلانيد (أدوية لعلاج مرض السكري)</p><p>&bull;&nbsp;&nbsp;&nbsp; الأمينوجلايكوسيدات (أحد أنواع المضادات الحيوية) بالمثل جنتاميسين، ستربتوميسين، توبراميسين، أميكاسين، نيتيلميسين</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>&nbsp;إذا كنت حاملاً، أو تعتقدين أنك قد تكونين حاملاً، أو إذا كنت مرضعة، استشيري طبيبك قبل أن تتناولي أقراص <strong>كلامايسين</strong>، حيث أن مدى&nbsp; سلامة استخدامهم أثناء الحمل والرضاعة الطبيعية ليست معروفة حتى الآن.</p><p><strong>القيادة وتشغيل الآلات </strong></p><p>قد يتسبب <strong>كلامايسين</strong> في الشعور بالدوخة، الدوار، الارتباك والضياع. في حال تعرضك لمثل هذه الأعراض لا تقم بقيادة أو استخدام الالآت .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب تناول أقراص <strong>كلامايسين</strong> دائماً بدقة وفقاً لتعليمات الطبيب. استشر طبيبك أو الصيدلي الذي تتعامل معه ما لم تكن متأكداً من طريقة الاستخدام. الجرعة الإعتيادية هي؛</p><p><strong>لعدوى الصدر، الحلق أو عدوى الجيوب الأنفية والجلد وعدوى الأنسجة الرخوة: </strong></p><p>الجرعة الإعتيادية للبالغين والأطفال أكبر من 12 سنة هي 250 ملغم مرتين يومياً لمدة سبعة أيام، على سبيل المثال قرص واحد من كلامايسين 250 ملغم في الصباح وقرص آخر في المساء.</p><p>قد يزيد طبيبك الجرعة إلى قرص واحد من <strong>كلامايسين</strong> 500 ملغم مرتين يومياً وذلك في حالات العدوى الحادة.</p><p>يجب ابتلاع أقراص <strong>كلامايسين</strong> مع ما لا يقل عن نصف كوب من الماء.</p><p>لا تعطي هذه الاقراص للأطفال أقل من 12 سنة. سوف يصف طبيبك دواء آخر مناسب لطفلك.</p><p><strong>لعلاج حالات العدوى التي تسببها أنواع معينة من البكتيريا تعرف باسم مايكوباكتيريا</strong></p><p>لعلاج مثل هذه الحالات يكون مقدار الجرعة الإعتيادية هو 500 ملغم مرتين يومياً. قد يزيد طبيبك الجرعة إلى 1000 ملغم مرتين يومياً ما لم تكن هناك أية استجابة للجرعة الأقل بعد مرور 3 - 4 أسابيع.</p><p>للوقاية من العدوى الناتجة عن مايكوباكتيريا، الجرعة الإعتيادية للبالغين هي 500 ملغم مرتين يومياً.</p><p><strong>لعلاج العدوى بهيليكوباكتر بيلوري المرتبطة مع الإصابة بقرحة الاثني عشر.</strong></p><p>هناك عدد من أنظمة العلاج المركب الفعالة المتاحة لعلاج هيليكوباكتر بيلوري والتي يتم من خلالها تناول أقراص <strong>كلامايسين</strong> بالتزامن مع واحد أو اثنين من الأدوية الأخرى.</p><p>وتشمل هذه الأنظمة العلاجية على ما يلي:</p><p><strong>أ&zwnj;)&nbsp;&nbsp;&nbsp; </strong>قرص واحد من <strong>كلامايسين </strong>500 ملغم يؤخذ مرتين يومياً بالتزامن مع الأموكسيسيلين 1000 ملغم، حيث يؤخذ مرتين يومياً مع مثبطات مضخة البروتون بالجرعة اليومية الموصى بها لمدة 7 أيام (7 أيام من العلاج الثلاثي).</p><p><strong>ب&zwnj;)&nbsp; </strong>قرص واحد من <strong>كلامايسين</strong> 500 ملغم&nbsp; يؤخذ مرتين يومياً بالتزامن مع مثبطات مضخة البروتون بالجرعة اليومية الموصى بها بالإضافة إلى 400 ملغم ميترونيدازول يؤخذ مرتين يومياً لمدة 7 أيام (7 أيام من العلاج الثلاثي)</p><p><strong>ج</strong>) &nbsp;&nbsp;قرص واحد من <strong>كلامايسين</strong> 500 ملغم&nbsp; يؤخذ مرتين يومياً بالتزامن مع الأموكسيسيلين 1000 ملغم ، حيث يؤخذ مرتين يومياً بالإضافة إلى أوميبرازول 20 ملغم تؤخذ مرة واحدة يومياً لمدة 7-10 أيام (7-10 أيام من العلاج الثلاثي).</p><p><strong>د</strong>)&nbsp;&nbsp; قرص واحد من <strong>كلامايسين</strong> 500 ملغم&nbsp; يؤخذ ثلاث مرات يومياً لمدة 14 يوم بالتزامن مع أوميبرازول 40 ملغم تؤخذ مرة واحدة يومياً (14 يوماً من العلاج المزدوج).</p><p>قد يختلف العلاج المركب الذي تتناوله اختلافاً طفيفاً عن الذي تم ذكره في الأعلى. سوف يقرر طبيبك النظام العلاجي المركب الأنسب لك.</p><p>يرجى منك استشارة الطبيب للحصول على المشورة، ما لم تكن متأكداً من الأقراص التي يجب عليك تناولها أو المدة التي يجب عليك الاستمرار في تناولها<strong>.</strong></p><p><strong>إذا كنت قد تناولت على سبيل الخطأ كلامايسين بجرعة أكبر مما ينبغي</strong></p><p>إذا كنت قد تناولت على سبيل&nbsp; الخطأ <strong>كلامايسين</strong> بجرعة أكبر مما ينبغي، أو إذا إبتلع أحد الأطفال بعض الأقراص على سبيل الخطأ. اتصل بطبيبك أو أقرب قسم طوارئ في المستشفى على الفور. حيث أن تناول جرعة زائدة من أقراص <strong>كلامايسين</strong> من المحتمل أن يتسبب في حدوث قيء وآلام في المعدة.</p><p><strong>إذا سهوت عن تناول </strong><strong>كلامايسين</strong></p><p>إذا سهوت عن تناول جرعة من <strong>كلامايسين</strong>، فيجب عليك تناول هذه الجرعة في أسرع&nbsp; وقت ممكن حال تذكرها. يجب عدم تجاوز مقدار الجرعة اليومية الموصى بها من قبل طبيبك المعالج. يجب عليك الاستمرار في تناول أقراصك حتى وإن كنت تشعر بتحسن، من الضروري تناول الأقراص للمدة التي وصفها لك الطبيب.<strong> </strong>وإلا فقد تعاود العدوى في الحدوث مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، قد يؤدي <strong>كلامايسين</strong>، إلى حدوث تأثيرات جانبية، ولكنها قد لا تحدث لكل شخص.</p><p>في حال تعرضك للإصابة بإسهال شديد أو لفترة زمنية طويلة، يصاحبه وجود دماء أو مخاط، أثناء تناولك <strong>كلامايسين</strong> أو بعد انتهاء العلاج، استشر طبيبك على الفور حيث أن هذه الأعراض قد تكون إشارة إلى وجود ظروف صحية أكثر خطورة بالمثل التهاب القولون الغشائي الكاذب أو الإسهال المرتبط حدوثه بالإصابة بكلوستيريديم ديفيسيل.</p><p>قد تحدث الإصابة بالإسهال على مدى أكثر من شهرين من بعد العلاج باستخدام كلاريثروميسين.</p><p>في حال تعرضك للإصابة بالطفح الجلدي، صعوبة في التنفس، إغماء أو تورم في الوجه والحلق، اتصل بطبيبك على الفور حيث أن هذه الأعراض قد تكون إشارة إلى وجود تفاعلات تحسسية وقد تستدعي الحاجة إلى الخضوع للعلاج الطارئ.</p><p>في حال تعرضك لفقدان الشهية، واصفرار الجلد (اليرقان)، بول داكن اللون، حكة أو ألم في منطقة البطن، اتصل بطبيبك على الفور حيث أن هذه الأعراض قد تكون إشارة إلى وجود فشل كبدي.</p><p>قد تشتمل التأثيرات الجانبية الأخرى على:</p><p><strong>شائعة (قد تصيب 1 إلى 10 أشخاص من كل 100 شخص)</strong></p><p>&bull;&nbsp; صعوبة في النوم (الأرق)</p><p>&bull;&nbsp; اضطراب حاسة التذوق</p><p>&bull;&nbsp; صداع</p><p>&bull;&nbsp; مشاكل في المعدة بالمثل الشعور بالإعياء، قيء، آلام في المعدة، عسر الهضم، إسهال</p><p>&bull;&nbsp; ظهور نتائج غير طبيعية لوظائف الكبد في فحوصات الدم&nbsp;</p><p>&bull;&nbsp; الطفح الجلدي، فرط التعرق وتوهج</p><p><strong>غير شائعة</strong> <strong>(قد تصيب 1 إلى 10 أشخاص من كل 1000 شخص)</strong></p><p>&bull;&nbsp; عدوى الجلد أو المهبل، والإصابة بعدوى فطرية (القلاع).</p><p>&bull;&nbsp; تغير في مستوى خلايا الدم البيضاء في الدم (مما يزيد من احتمالية الإصابة بالعدوى)</p><p>&bull;&nbsp; تغير في مستويات الصفائح الدموية في الدم (مما يزيد من خطر حدوث الكدمات، النزيف أو جلطات الدم)</p><p>&bull;&nbsp; تفاعلات تحسسية</p><p>&bull;&nbsp; انخفاض الشهية</p><p>&bull;&nbsp; قلق، شعور بالعصبية ورغبة في الصراخ</p><p>&bull;&nbsp; إغماء، دوخة، نعاس، رعاش، حركات لا إرادية في اللسان والوجه والشفاه أو الأطراف</p><p>&bull;&nbsp; دوار، طنين في الأذن، فقدان السمع</p><p>&bull;&nbsp; سرعة ضربات القلب وخفقان، تغيرات في ضربات القلب أو توقف القلب</p><p>&bull;&nbsp; &nbsp;مشاكل في التنفس (الربو)، نزيف أنفي</p><p>&bull;&nbsp; &nbsp;تجلط الدم في الرئتين</p><p>&bull;&nbsp; مشاكل في المعدة بالمثل انتفاخ، إمساك، ريح (انتفاخ البطن)، التجشؤ، حرقة المعدة أو ألم في الشرج</p><p>&bull;&nbsp; التهاب بطانة المعدة أو المريء (الأنبوب الذي يربط فمك مع معدتك)</p><p>&bull;&nbsp; التهاب الفم، جفاف الفم، والتهاب اللسان</p><p>&bull;&nbsp; مشاكل في الكبد بالمثل التهاب الكبد أو الركود الصفراوي مما قد يسبب اصفرار الجلد (اليرقان)، براز شاحب اللون أو بول داكن اللون</p><p>&bull;&nbsp; ارتفاع مستويات انزيمات الكبد</p><p>&bull;&nbsp; حكة، شرى، التهاب الجلد</p><p>&bull;&nbsp; تيبس وآلام أو تقلص العضلات</p><p>&bull;&nbsp; مشاكل في الكلى بالمثل ارتفاع مستويات البروتين التي عادة ما تفرز بواسطة الكلى أو ارتفاع مستويات انزيمات الكلى</p><p>&bull;&nbsp; حمى، قشعريرة، شعور بالوهن، والتعب، ألم في الصدر أو شعور عام بعدم الارتياح</p><p>&bull;&nbsp; ظهور نتائج غير طبيعية لفحوصات الدم</p><p><strong>غير معروفه (لا يمكن تقدير تكرر حدوثها من البيانات المتاحة): </strong></p><p>&bull;&nbsp; عدوى القولون</p><p>&bull;&nbsp; عدوى الجلد أو طيات الجلد</p><p>&bull;&nbsp; انخفاض مستويات السكر في الدم الذي قد يسبب الإغماء</p><p>&bull;&nbsp; اضطرابات ذهنية، ارتباك، اضطراب الوعي، اكتئاب، توهان، هلوسة (رؤية أشياء غير موجودة بالواقع)، أحلام غير طبيعية (الكوابيس).</p><p>&bull;&nbsp; تشنجات</p><p>&bull;&nbsp; اضطراب أو فقدان في حاسة الذوق و / أو حاسة الشم</p><p>&bull;&nbsp; خدر (شعور الوخز وحرقان في الجلد، تنميل، إحساس كوخز الأبر والدبابيس)</p><p>&bull;&nbsp; الصمم</p><p>&bull;&nbsp; النزيف</p><p>&bull;&nbsp; التهاب البنكرياس</p><p>&bull;&nbsp; تلون اللسان، تغير لون الأسنان</p><p>&bull;&nbsp; فشل الكبد، واليرقان (اصفرار الجلد)</p><p>&bull;&nbsp; ردود فعل تحسسية جلدية نادرة بالمثل متلازمة ستيفنز جونسون أو انحلال البشرة السمي التنخري (التي تسبب مرض شديد مع ظهور تقرح في الفم والشفتين والجلد)، متلازمة دي أر إي أس أس (التي قد تسبب مرض شديد مصحوب بطفح جلدي وحمى والتهاب الأعضاء الداخلية) أو فرفرية هينوك شونلابن (التي تسبب بقع أرجوانية اللون على الجلد، آلام المفاصل، الجهاز الهضمي ومشاكل في الكلى).</p><p>&bull;&nbsp; حب الشباب</p><p>&bull;&nbsp; مرض في العضلات (اعتلال عضلي)، وانهيار الأنسجة العضلية (انحلال الربيدات)</p><p>&bull;&nbsp; التهاب الكلى (الذي يمكن أن يسبب تورم الكاحلين أو ارتفاع ضغط الدم) أو الفشل الكلوي</p><p>كما وردت تقارير أخرى تشير إلى أن كلاريثروميسين قد يؤدي إلى تفاقم أعراض الوهن العضلي الوبيل (مرض تصبح فيه العضلات ضعيفة والشعور بالتعب بسهولة) لدى المرضى الذين يعانون فعلياً من هذا المرض.</p><p><strong>في حال تعرضك لأية تأثيرات جانبية بما في ذلك أية تأثيرات جانبية أخرى يحتمل حدوثها ولم تذكر في هذه النشرة، يرجى إخبار طبيبك أو الصيدلي الذي تتعامل معه. </strong></p><p><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong><br /><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p><strong>رقم الفاكس: </strong>7662-205-11-966+</p><p><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على: </strong>2038222-11<strong>-</strong>966+<strong>&nbsp; </strong></p><p><strong>وصلة هاتف:</strong>2340-2334-2354-2353-2356-2317</p><p><strong>الهاتف المجاني: </strong>8002490000</p><p><strong>البريد الإلكتروني:</strong><strong> </strong>&nbsp;npc.drug@sfda.gov.sa</p><p><strong>الموقع الإلكتروني:</strong> www.sfda.gov.sa/npc</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>-&nbsp; </strong>يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p>-&nbsp; يجب عدم تناول <strong>كلامايسين</strong> بعد انتهاء تاريخ الصلاحية المذكور على العبوة والشريط ، يشير تاريخ إنتهاء الصلاحية إلى آخر يوم من الشهر المذكور</p><p>-&nbsp; يحفظ في درجة حرارة أقل من 30˚م.</p><p>-&nbsp; يجب عدم تناول <strong>كلامايسين</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p>-&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي<strong> </strong>كلاريثروميسين. يحتوي كل قرص مكسو على:&nbsp; كلاريثروميسين 250 ملغم أو 500 ملغم</p><p>المواد الأخرى: سليلوز دقيق البلورات، كروس كارميلوز الصوديوم، بوفيدون، بولي سوربات، نشا، استيارات المغنيسيوم، تلك، حمض الاستياريك، إيروسيل، هيبروميللوز، بولي إيثيلين جلايكول، ثنائي أكسيد التيتانيوم، ودي وسي أصفر رقم 10 لاك.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            تتوفر أقراص كلامايسين المكسوة في عبوات تحتوي كلاً منها على 14 قرصاً


        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية&quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
23/01/2017

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clamycin 250mg Film-coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains:
Item No.	Material Name	Scale (mg/Tablet)
		
	Active Ingredient:	
1.		Clarithromycin 	250.00
		
	Inactive Ingredients:	
1.		Croscarmellose Sodium (Ac-Di-Sol)	18.00
2.		Polyvinyl Pyrrolidone K-30 (PVP K-30)	9.00
3.		Pregelatinized Starch (Starch 1500)	22.00
4.		Magnesium Stearate 	2.25
5.		Colloidal Silicon Dioxide (Aerosil 200)	1.75
6.		Talc Fine powder 	4.50
7.		Polysorbate 80 (Tween 80)	1.10
8.		Stearic Acid 	3.00
9.		Microcrystalline Cellulose (Avicel PH 102)	q.s. to 450.00
10.		Ethanol 95% *	85.00
		
	Coating Materials:	
1.		Hypromellose (Hydroxypropyl MethylCellulose)	5.50
2.		Polyethylene Glycol 4000	0.90
3.		Titanium Dioxide 	1.00
4.		Talc Fine Powder 	2.00
5.		D&C Yellow No. 10 Lake 	0.60
6.		Purified Water * 	q.s. 
7.		Ethanol 95% *	q.s.

* Evaporates during manufacturing process and does not appear in the final product. 
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-Coated tablets
Description: Yellow, oblong, biconvex film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clarithromycin is indicated for the treatment of infections due to susceptible organisms. Such infections include:</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lower respiratory tract infections (e.g. bronchitis, pneumonia) (see section 4.4 and 5.1 regarding Sensitivity Testing).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upper respiratory tract infections (e.g. pharyngitis, sinusitis).</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipelas) (see section 4.4 and 5.1 regarding Sensitivity Testing).</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disseminated or localised mycobacterial infections due to&nbsp;<em>Mycobacterium avium</em>&nbsp;or&nbsp;<em>Mycobacterium intracellulare</em>. Localised infections due to&nbsp;<em>Mycobacterium chelonae</em>,&nbsp;<em>Mycobacterium fortuitum</em>&nbsp;or&nbsp;<em>Mycobacterium kansasii</em>.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clarithromycin is indicated for the prevention of disseminated&nbsp;<em>Mycobacterium avium</em>&nbsp;complex infection in HIV-infected patients with CD4 lymphocyte counts less than or equal to 100/mm<sup>3</sup>.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clarithromycin in the presence of acid suppression is indicated for the eradication of&nbsp;<em>H. pylori</em>, resulting in decreased recurrence of duodenal ulcer. (See further information).</p><p>Clarithromycin tablets are indicated in adults and children 12 years and older.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p><p><strong>Further Information:&nbsp;</strong><em>H. pylori</em> is strongly associated with peptic ulcer disease. Ninety to 100% of patients with duodenal ulcers are infected with this agent. Eradication of&nbsp;<em>H. pylori</em>&nbsp;has been shown to markedly reduce the rate of duodenal ulcer recurrence, thereby reducing the need for maintenance anti-secretory therapy.</p><p>In a well-controlled double-blind study,&nbsp;<em>H. pylori</em>&nbsp;infected patients with duodenal ulcer received clarithromycin 500mg t.i.d for 14 days with omeprazole 40mg daily for 28 days.</p><p>Clarithromycin has been used in other treatment regimens for the eradication of&nbsp;<em>H. pylori</em>. These regimens include: clarithryomycin plus tinidazole and omeprazole; and clarithromycin plus tetracycline, bismuth subsalicylate and ranitidine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults:</strong> The usual recommended dosage of clarithromycin in adults is one 250mg tablet twice daily. In more severe infections, the dosage can be increased to 500mg twice daily. The usual duration of therapy is 6 to 14 days.</p><p><strong>Children under 12 years:</strong> The use of clarithromycin tablets has not been studied in children under 12 years. Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension (granules for oral suspension).</p><p><strong>Children over 12 years: </strong>As for adults.</p><p>In patients with renal impairment with creatinine clearance less than 30 ml/min, the dosage of clarithromycin should be reduced by one-half, i.e: 250mg once daily or 250mg twice daily in more severe infections. Treatments should not be continued beyond 14 days in these patients.</p><p><strong>Dosage in patients with mycobacterial infections:</strong> The recommended dose for adults with mycobacterial infections is 500mg b.i.d. Treatment of disseminated&nbsp;<em>Mycobacterium avium</em>&nbsp;complex (MAC) infections in AIDS patients should be continued, as long as clinical microbiological benefit is demonstrated. Clarithromycin should be used in conjunction with other antimycobacterial agents.</p><p>Treatment of other non-tuberculous mycobacterial infections should continue at the discretion of the physician.</p><p><strong>Dosage for MAC prophylaxis:</strong> The recommended dosage of clarithromycin in adults is 500mg twice daily.</p><p><strong>Eradication of H. pylori:</strong></p><p>&sect; Triple Therapy (7 days): Clarithromycin (500mg) twice daily and a proton pump inhibitor (at the approved daily dose)* should be given with amoxicillin 1000mg twice daily for 7 days.</p><p>&sect; Triple Therapy (7 days): Clarithromycin (500mg) twice daily and a proton pump inhibitor (at the approved daily dose)* should be given with metronidazole 400mg twice daily for 7 days.</p><p>&sect; Triple Therapy (7-10 days): Clarithromycin (500mg) twice daily should be given with omeprazole 20mg daily and amoxicillin 1000mg twice daily for 7-10 days.</p><p>* see individual data sheets/SPCs for the dose recommendations for&nbsp;<em>H. pylori</em>&nbsp;eradication.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clarithromycin is contraindicated in patients with known hypersensitivity to macrolide antibiotic drugs or any of its excipients (see section 6.1).
Concomitant administration of clarithromycin and any of the following drugs is contraindicated: astemizole, cisapride, pimozide or terfenadine as this may result in QT prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes (see section 4.5).
Concomitant administration with ticagrelor or ranolazine is contraindicated.
Concomitant administration of clarithromycin and ergot alkaloids (e.g. ergotamine or dihydroergotamine) is contraindicated, as this may result in ergot toxicity (see section 4.5).
Clarithromycin should not be given to patients with history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes (see sections 4.4 and 4.5).
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolised by CYP3A4, (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see section 4.4).
As with other strong CYP3A4 inhibitors, clarithromycin should not be used in patients taking colchicine (see sections 4.4 and 4.5).
Concomitant administration of clarithromycin and oral midazolam is contraindicated (see section 4.5).
Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of QT-time).
Clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The physician should not prescribe clarithromycin to pregnant women without carefully weighing the benefits against risk; particularly during the first three months of pregnancy (see section 4.6).</p><p>Caution is advised in patients with severe renal insufficiency (see section 4.2).</p><p>Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications. Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur, such as anorexia, jaundice, dark urine, pruritus, or tender abdomen.</p><p>Clarithromycin is principally excreted by the liver. Therefore caution should be exercised in administering the antibiotic to patients with impaired hepatic function. Caution should also be exercised when administering clarithromycin to patients with moderate to severe renal impairment.</p><p>Cases of fatal hepatic failure (see section 4.8) have been reported. Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products. Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender abdomen.</p><p>Pseudomembranous colitis has been reported with nearly all antibacterial agents, including macrolides, and may range in severity from mild to life-threatening.&nbsp;<em>Clostridium difficile</em>&nbsp;associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents including clarithromycin, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of C.&nbsp;<em>difficile.&nbsp;</em>CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. Therefore, discontinuation of clarithromycin therapy should be considered regardless of the indication. Microbial testing should be performed and adequate treatment initiated. Drugs inhibiting peristalsis should be avoided.</p><p><strong><u>Colchicine</u></strong></p><p>There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been reported in some such patients (see section 4.5). Concomitant administration of clarithromycin and colchicine is contraindicated (see section 4.3).</p><p>Caution is advised regarding concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam, and intravenous or (oromucosal) midazolam (see section 4.5).</p><p><strong><u>Prolongation of the QT interval</u></strong></p><p>Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and torsade de pointes, have been seen in treatment with macrolides including clarithromycin (see section 4.8). Therefore as the following situations may lead to an increased risk for ventricular arrhythmias (including torsade de pointes), clarithromycin should be used with caution in the following patients:</p><p>&sect; Patients with coronary artery disease, severe cardiac insufficiency, conduction disturbances or clinically relevant bradycardia.</p><p>&sect; Patients with electrolyte disturbances such as hypomagnesaemia. Clarithromycin must not be given to patients with hypokalaemia (see section 4.3).</p><p>&sect; Patients concomitantly taking other medicinal products associated with QT prolongation (see section 4.5).</p><p>&sect; Concomitant administration of clarithomycin with astemizole, cisapride, pimozide and terfenadine is contraindicated (see section 4.3).</p><p>&sect; Clarithromycin must not be used in patients with congenital or documented acquired QT prolongation or history of ventricular arrhythmia (see section 4.3).</p><p><strong><u>Pneumonia</u></strong><strong>:</strong> In view of the emerging resistance of&nbsp;<em>Streptococcus pneumoniae</em>&nbsp;to macrolides, it is important that sensitivity testing be performed when prescribing clarithromycin for community-acquired pneumonia. In hospital-acquired pneumonia, clarithromycin should be used in combination with additional appropriate antibiotics.</p><p><strong><u>Skin and soft tissue infections of mild to moderate severity</u></strong><strong>:</strong> These infections are most often caused by&nbsp;<em>Staphylococcus aureus</em>&nbsp;and&nbsp;<em>Streptococcus pyogenes</em>, both of which may be resistant to macrolides. Therefore, it is important that sensitivity testing be performed. In cases where&nbsp;<em>beta</em>&ndash;lactam antibiotics cannot be used (e.g. allergy), other antibiotics, such as clindamycin, may be the drug of first choice. Currently, macrolides are only considered to play a role in some skin and soft tissue infections, such as those caused by&nbsp;<em>Corynebacterium minutissimum</em>&nbsp;, acne vulgaris, and erysipelas and in situations where penicillin treatment cannot be used.</p><p>In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.</p><p>Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme (see section 4.5).</p><p><strong><u>HMG-CoA Reductase Inhibitors (statins)</u></strong><strong>:</strong>&nbsp;Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see section 4.3).</p><p>Caution should be exercised when prescribing clarithromycin with other statins. Rhabdomyolysis has been reported in patients taking clarithromycin and statins. Patients should be monitored for signs and symptoms of myopathy. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the statin. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered (see section 4.5).</p><p><strong><u>Oral hypoglycaemic agents/insulin</u></strong><strong>:</strong>&nbsp;The concomitant use of clarithromycin and oral hypoglycaemic agents (such as sulphonylurias) and/or insulin can result in significant hypoglycaemia. Careful monitoring of glucose is recommended (see section 4.5).</p><p><strong><u>Oral anticoagulants</u></strong><strong>:</strong> There is a risk of serious haemorrhage and significant elevations in International Normalised Ratio (INR) and prothrombin time when clarithromycin is co-administered with warfarin (see section 4.5). INR and prothrombin times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.</p><p>Use of any antimicrobial therapy, such as clarithromycin, to treat&nbsp;<em>H. pylori&nbsp;</em>infection may select for drug-resistant organisms.</p><p>Long-term use may, as with other antibiotics, result in colonisation with increased numbers of non-susceptible bacteria and fungi. If super infections occur, appropriate therapy should be instituted.</p><p>Attention should also be paid to the possibility of cross resistance between clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>The use of the following drugs is strictly contraindicated due to the potential for severe drug interaction effects:</strong></p><p><u>Cisapride, pimozide, astemizole and terfenadine</u></p><p>Elevated cisapride levels have been reported in patients receiving clarithromycin and cisapride concomitantly. This may result in QT prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsades de pointes. Similar effects have been observed in patients taking clarithromycin and pimozide concomitantly (see section 4.3).</p><p>Macrolides have been reported to alter the metabolism of terfenadine resulting in increased levels of terfenadine which has occasionally been associated with cardiac arrhythmias, such as QT prolongation, ventricular tachycardia, ventricular fibrillation and torsades de pointes (see section 4.3). In one study in 14 healthy volunteers, the concomitant administration of clarithromycin and terfenadine resulted in a 2 to 3-fold increase in the serum level of the acid metabolite of terfenadine and in prolongation of the QT interval which did not lead to any clinically detectable effect. Similar effects have been observed with concomitant administration of astemizole and other macrolides.</p><p><u>Ergotamine/dihydroergotamine</u></p><p>Post-marketing reports indicate that co-administration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterised by vasospasm, and ischaemia of the extremities and other tissues including the central nervous system. Concomitant administration of clarithromycin and these medicinal products is contraindicated (see section 4.3).</p><p><u>Oral Midazolam</u></p><p>When midazolam was co-administered with clarithromycin tablets (500mg twice daily), midazolam AUC was increased 7-fold after oral administration of midazolam. Concomitant administration of oral midazolam and clarithromycin is contraindicated (see section 4.3).</p><p><u>HMG-CoA Reductase Inhibitors (statins)</u></p><p>Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see section 4.3) as these statins are extensively metabolized by CYP3A4 and concomitant treatment with clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Reports of rhabdomyolysis have been received for patients taking clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.</p><p>Caution should be exercised when prescribing clarithromycin with statins. In situations where the concomitant use of clarithromycin with statins cannot be avoided, it is recommended to prescribe the lowest registered dose of the statin. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered. Patients should be monitored for signs and symptoms of myopathy.</p><p><strong>Effects of other Medicinal Products on Clarithromycin</strong></p><p>Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St John&#39;s wort) may induce the metabolism of clarithromycin. This may result in sub-therapeutic levels of clarithromycin leading to reduced efficacy. Furthermore, it might be necessary to monitor the plasma levels of the CYP3A inducer, which could be increased owing to the inhibition of CYP3A by clarithromycin (see also the relevant product information for the CYP3A4 inhibitor administered). Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis.</p><p>The following drugs are known or suspected to affect circulating concentrations of clarithromycin; clarithromycin dosage adjustment or consideration of alternative treatments may be required.</p><p><u>Efavirenz, nevirapine, rifampicin, rifabutin and rifapentine</u></p><p>Strong inducers of the cytochrome P450 metabolism system such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine may accelerate the metabolism of clarithromycin and thus lower the plasma levels of clarithromycin, while increasing those of 14-OH-clarithromycin, a metabolite that is also microbiologically active. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers.</p><p><u>Etravirine</u></p><p>Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity against&nbsp;<em>Mycobacterium avium</em>&nbsp;complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.</p><p><u>Fluconazole</u></p><p>Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state minimum clarithromycin concentration (C<sub>min</sub>) and area under the curve (AUC) of 33% and 18% respectively. Steady state concentrations of the active metabolite 14-OH-clarithromycin were not significantly affected by concomitant administration of fluconazole. No clarithromycin dose adjustment is necessary.</p><p><u>Ritonavir</u></p><p>A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours resulted in a marked inhibition of the metabolism of clarithromycin. The clarithromycin C<sub>max</sub>&nbsp;increased by 31%, C<sub>min</sub>&nbsp;increased 182% and AUC increased by 77% with concomitant administration of ritonavir. An essentially complete inhibition of the formation of 14-OH-clarithromycin was noted. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with creatinine clearance 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with creatinine clearance &lt;30 mL/min the dose of clarithromycin should be decreased by 75%. Doses of clarithromycin greater than 1000 mg/day should not be coadministered with ritonavir.</p><p>Similar dose adjustments should be considered in patients with reduced renal function when ritonavir is used as a pharmacokinetic enhancer with other HIV protease inhibitors including atazanavir and saquinavir (see section below, Bi-directional drug interactions).</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Effect of Clarithromycin on Other Medicinal Products</strong></p><p><u>CY3A4-based interactions</u></p><p>Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolised by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug. Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g. carbamazepine) and/or the substrate is extensively metabolised by this enzyme.</p><p>Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolised by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.</p><p>The following drugs or drug classes are known or suspected to be metabolised by the same CYP3A isozyme: alprazolam, astemizole, carbamazepine, cilostazol, cisapride, cyclosporine, disopyramide, ergot alkaloids, lovastatin, methylprednisolone, midazolam, omeprazole, oral anticoagulants (e.g. warfarin, see section 4.4), atypical antipsychotics (e.g. quetiapine), pimozide, quinidine, rifabutin, sildenafil, simvastatin, sirolimus, tacrolimus, terfenadine, triazolam and vinblastine. Drugs interacting by similar mechanisms through other isozymes within the cytochrome P450 system include phenytoin, theophylline and valproate.</p><p><u>Antiarrhythmics</u></p><p>There have been postmarketed reports of torsades de points occurring with the concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QT prolongation during co-administration of clarithromycin with these drugs. Serum levels of quinidine and disopyramide should be monitored during clarithromycin therapy.</p><p>There have been post marketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.</p><p><u>Oral hypoglycemic agents/Insulin</u></p><p>With certain hypoglycemic drugs such as nateglinide and repaglinide, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypoglycaemia when used concomitantly. Careful monitoring of glucose is recommended.</p><p><u>Omeprazole</u></p><p>Clarithromycin (500 mg every 8 hours) was given in combination with omeprazole (40 mg daily) to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (C<sub>max</sub>, AUC<sub>0-24</sub>, and t<sub>1/2</sub>&nbsp;increased by 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when omeprazole was co-administered with clarithromycin.</p><p><u>Sildenafil, tadalafil and vardenafil</u></p><p>Each of these phosphodiesterase inhibitors is metabolised, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil or vardenafil would likely result in increased phosphodiesterase inhibitor exposure. Reduction of sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co-administered with clarithromycin.</p><p><u>Theophylline and carbamazepine</u></p><p>Results of clinical studies indicate that there was a modest but statistically significant (p&le; 0.05) increase of circulating theophylline or carbamazepine levels when either of these drugs were administered concomitantly with clarithromycin. Dose reduction may need to be considered.</p><p><u>Tolterodine</u></p><p>The primary route of metabolism for tolterodine is via the 2D6 isoform of cytochrome P450 (CYP2D6). However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. A reduction in tolterodine dosage may be necessary in the presence of CYP3A inhibitors, such as clarithromycin in the CYP2D6 poor metabolizer population.</p><p><u>Triazolobenzodiazepines (e.g. alprazolam, midazolam, triazolam)</u></p><p>When midazolam was co-administered with clarithromycin tablets (500 mg twice daily), midazolam AUC was increased 2.7-fold after intravenous administration of midazolam. If intravenous midazolam is co-administered with clarithromycin, the patient must be closely monitored to allow dose adjustment. A drug-drug interaction study between oromucosal midazolam and clarithromycin has not been conducted. However drug delivery of midazolam via oromucosal route, which could bypass pre-systemic elimination of the drug, will likely result in a similar interaction to that observed after intravenous midazolam rather than oral administration. The same precautions should also apply to other benzodiazepines that are metabolized by CYP3A, including triazolam and alprazolam. For benzodiazepines which are not dependent on CYP3A for their elimination (temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.</p><p><strong>Other drug interactions</strong></p><p><u>Colchicine</u></p><p>Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure to colchicine. Concomitant use of clarithromycin and colchicine is contraindicated (see sections 4.3 and 4.4).</p><p><u>Digoxin</u></p><p>Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp). Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered together, inhibition of Pgp by clarithromycin may lead to increased exposure to digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have also been reported in post-marketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.</p><p><u>Zidovudine</u></p><p>Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Because clarithromycin appears to interfere with the absorption of simultaneously administered oral zidovudine, this interaction can be largely avoided by staggering the doses of clarithromycin and zidovudine to allow for a 4-hour interval between each medication. This interaction does not appear to occur in paediatric HIV-infected patients taking clarithromycin suspension with zidovudine or dideoxyinosine. This interaction is unlikely when clarithromycin is administered via intravenous infusion.</p><p><u>Phenytoin and valproate</u></p><p>There have been spontaneous or published reports of interactions of CYP3A inhibitors, including clarithromycin with drugs not thought to be metabolised by CYP3A (e.g. phenytoin and valproate). Serum level determinations are recommended for these drugs when administered concomitantly with clarithromycin. Increased serum levels have been reported.</p><p><strong>Bi-directional drug interactions</strong></p><p><u>Atazanavir</u></p><p>Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Co-administration of clarithromycin (500 mg twice daily) with atazanavir (400 mg once daily) resulted in a 2-fold increase in exposure to clarithromycin and a 70% decrease in exposure to 14-OH-clarithromycin, with a 28% increase in the AUC of atazanavir. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. For patients with moderate renal function (creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should be decreased by 50%. For patients with creatinine clearance &lt;30 mL/min, the dose of clarithromycin should be decreased by 75% using an appropriate clarithromycin formulation. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.</p><p><u>Calcium Channel Blockers</u></p><p>Caution is advised regarding the concomitant administration of clarithromycin and calcium channel blockers metabolized by CYP3A4 (e.g. verapamil, amlodipine, diltiazem) due to the risk of hypotension. Plasma concentrations of clarithromycin as well as calcium channel blockers may increase due to the interaction. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients taking clarithromycin and verapamil concomitantly.</p><p><u>Itraconazole</u></p><p>Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading to a bi-directional drug interaction. Clarithromycin may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effect.</p><p><u>Saquinavir</u></p><p>Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Concomitant administration of clarithromycin (500 mg twice daily) and saquinavir (soft gelatin capsules, 1200 mg three times daily) to 12 healthy volunteers resulted in steady-state AUC and C<sub>max</sub>&nbsp;values of saquinavir which were 177% and 187% higher than those seen with saquinavir alone. Clarithromycin AUC and C<sub>max</sub>&nbsp;values were approximately 40% higher than those seen with clarithromycin alone. No dose adjustment is required when the two drugs are co-administered for a limited time at the doses/formulations studied. Observations from drug interaction studies using the soft gelatin capsule formulation may not be representative of the effects seen using the saquinavir hard gelatin capsule. Observations from drug interaction studies performed with saquinavir alone may not be representative of the effects seen with saquinavir/ritonavir therpy. When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (see section 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>The safety of clarithromycin for use in pregnancy has not been established. Based on variable results obtained from studies in mice, rats, rabbits and monkeys, the possibility of adverse effects on embyofoetal development cannot be excluded. Therefore, use during pregnancy is not advised without carefully weighing the benefits against risk.</p><p><strong><u>Lactation</u></strong></p><p>The safety of clarithromycin use during breast-feeding of infants has not been established. Clarithromycin is excreted into human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on the effect of clarithromycin on the ability to drive or use machines. The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>a. Summary of the safety profile</strong></p><p>The most frequent and common adverse reactions related to clarithromycin therapy for both adult and paediatric populations are abdominal pain, diarrhoea, nausea, vomiting and taste perversion. These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics. (see section b. of section 4.8)</p><p>There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without preexisting mycobacterial infections.</p><p><strong>b. Tabulated summary of adverse reactions</strong></p><p>The following table displays adverse reactions reported in clinical trials and from post-marketing experience with clarithromycin immediate-release tablets, granules for oral suspension, powder for solution for injection, extended-release tablets and modified-release tablets.</p><p>The reactions considered at least possibly related to clarithromycin are displayed by system organ class and frequency using the following convention: very common (&ge;1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge;1/1,000 to &lt; 1/100) and not known (adverse reactions from post-marketing experience; frequency cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed.</p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><tbody><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very common</p><p>(&ge;1/10</p></td><td style="vertical-align:top"><p>Common</p><p>&ge; 1/100 to &lt; 1/10</p></td><td style="vertical-align:top"><p>Uncommon</p><p>&ge;1/1,000 to &lt; 1/100</p></td><td style="vertical-align:top"><p>Not Known</p><p>(*cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cellulitis<sup>1</sup>, candidiasis, gastroenteritis<sup>2</sup>,infection<sup>3</sup>, vaginal infection</p></td><td style="vertical-align:top"><p>Pseudomembranous colitis, erysipelas</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Leukopenia, neutropenia<sup>4</sup>, thrombocythemia<sup>3</sup>, eosinophilia<sup>4</sup></p></td><td style="vertical-align:top"><p>Agranulocytosis, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactoid reaction<sup>1</sup>, hypersensitivity</p></td><td style="vertical-align:top"><p>Anaphylactic reaction, angioedema</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anorexia, decreased appetite</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety, nervousness<sup>3</sup>,</p></td><td style="vertical-align:top"><p>Psychotic disorder, confusional state, depersonalisation, depression, disorientation, hallucination, abnormal dreams, mania</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dysgeusia, headache, taste perversion</p></td><td style="vertical-align:top"><p>Loss of consciousness<sup>1</sup>, dyskinesia<sup>1</sup>, dizziness, somnolence, tremor</p></td><td style="vertical-align:top"><p>Convulsion, ageusia, parosmia, anosmia, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vertigo, hearing impaired, tinnitus</p></td><td style="vertical-align:top"><p>Deafness</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Cardiac arrest<sup>1</sup>, atrial fibrillation<sup>1</sup>, electrocardiogram QT prolonged, extrasystoles<sup>1</sup>, palpitations</p></td><td style="vertical-align:top"><p>Torsades de pointes, ventricular tachycardia, ventricular fibrillation</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vasodilation<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorder</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Asthma<sup>1</sup>, epistaxis<sup>2</sup>, pulmonary embolism<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Diarrhoea, vomiting, dyspepsia, nausea, abdominal pain</p></td><td style="vertical-align:top"><p>Oesophagitis<sup>1</sup>, gastrooesophageal reflux disease<sup>2</sup>, gastritis, proctalgia<sup>2</sup>, stomatitis, glossitis, abdominal distension<sup>4</sup>, constipation, dry mouth, eructation, flatulence</p></td><td style="vertical-align:top"><p>Pancreatitis acute, tongue discolouration, tooth discolouration</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Liver function test abnormal</p></td><td style="vertical-align:top"><p>Cholestasis<sup>4</sup>, hepatitis<sup>4</sup>, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyltransferase increased<sup>4</sup></p></td><td style="vertical-align:top"><p>Hepatic failure, jaundice hepatocellular</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash, hyperhidrosis</p></td><td style="vertical-align:top"><p>Dermatitis bullous<sup>1</sup>, pruritus, urticaria, rash maculo-papular<sup>3</sup></p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), acne</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Muscle spasms<sup>3</sup>, musculoskeletal stiffness<sup>1</sup>, myalgia<sup>2</sup></p></td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>2, **</sup>, myopathy</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Blood creatinine increased<sup>1</sup>, blood urea increased<sup>1</sup></p></td><td style="vertical-align:top"><p>Renal failure, nephritis interstitial</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site phlebitis<sup>1</sup></p></td><td style="vertical-align:top"><p>Injection site pain<sup>1</sup>, injection site inflammation<sup>1</sup></p></td><td style="vertical-align:top"><p>Malaise<sup>4</sup>, pyrexia<sup>3</sup>, asthenia, chest pain<sup>4</sup>, chills<sup>4</sup>, fatigue<sup>4</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Albumin globulin ratio abnormal<sup>1</sup>, blood alkaline phosphatase increased<sup>4</sup>, blood lactate dehydrogenase increased<sup>4</sup></p></td><td style="vertical-align:top"><p>International normalised ratio increased, prothrombin time prolonged, urine colour abnormal</p></td></tr></tbody></table><p><sup>*&nbsp;</sup>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Patient exposure is estimated to be greater than 1 billion patient treatment days for clarithromycin.</p><p><sup>**&nbsp;</sup>In some reports of rhabdomyolysis, clarithromycin was administered concomitantly with other drugs known to be associated with rhabdomyolysis (such as statins, fibrates, colchicine or allopurinol).</p><p><sup>1&nbsp;</sup>ADRs reported only for the Powder for Solution for Injection formulation</p><p><sup>2</sup>ADRs reported only for the Extended-Release Tablets formulation</p><p><sup>3&nbsp;</sup>ADRs reported only for the Granules for Oral Suspension formulation</p><p><sup>4&nbsp;</sup>ADRs reported only for the Immediate-Release Tablets formulation</p><p><strong>c. Description of selected adverse reactions</strong></p><p>Injection site phlebitis, injection site pain, vessel puncture site pain, and injection site inflammation are specific to the clarithromycin intravenous formulation.</p><p>In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol (see section 4.3 and 4.4).</p><p>There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested (see section 4.5).</p><p>There have been rare reports of clarithromycin extended-release tablets in the stool, many of which have occurred in patients with anatomic (including ileostomy or colostomy) or functional gastrointestinal disorders with shortened GI transit times. In several reports, tablet residues have occurred in the context of diarrhoea. It is recommended that patients who experience tablet residue in the stool and no improvement in their condition should be switched to a different clarithromycin formulation (e.g. suspension) or another antibiotic.</p><p>Special population: Adverse Reactions in Immunocompromised Patients (see section e).</p><p><strong><em>d. Paediatric populations</em></strong></p><p>Clinical trials have been conducted using clarithromycin paediatric suspension in children 6 months to 12 years of age. Therefore, children under 12 years of age should use clarithromycin paediatric suspension.</p><p>Frequency, type and severity of adverse reactions in children are expected to be the same as in adults.</p><p><strong>e.&nbsp;Other special populations</strong></p><p><em><u>Immunocompromised patients</u></em></p><p>In AIDS and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of Human Immunodeficiency Virus (HIV) disease or intercurrent illness.</p><p>In adult patients, the most frequently reported adverse reactions by patients treated with total daily doses of 1000mg and 2000mg of clarithromycin were: nausea, vomiting, taste perversion, abdominal pain, diarrhoea, rash, flatulence, headache, constipation, hearing disturbance, Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvate Transaminase (SGPT) elevations. Additional low-frequency events included dyspnoea, insomnia and dry mouth. The incidences were comparable for patients treated with 1000mg and 2000mg, but were generally about 3 to 4 times as frequent for those patients who received total daily doses of 4000mg of clarithromycin.</p><p>In these immunocompromised patients evaluations of laboratory values were made by analysing those values outside the seriously abnormal level (i.e. the extreme high or low limit) for the specified test. On the basis of these criteria, about 2% to 3% of those patients who received 1000mg or 2000mg of clarithromycin daily had seriously abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower percentage of patients in these two dosage groups also had elevated Blood Urea Nitrogen (BUN) levels. Slightly higher incidences of abnormal values were noted for patients who received 4000mg daily for all parameters except White Blood Cell.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effect(s):</u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2353-2354-2334-2340.</p><p><strong>Toll free phone:</strong> 8002490000</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reports indicate that the ingestion of large amounts of clarithromycin can be expected to produce gastrointestinal symptoms. One patient who had a history of bipolar disorder ingested eight grams of clarithromycin and showed altered mental status, paranoid behaviour, hypokalemia, and hypoxaemia.</p><p>Adverse reactions accompanying overdosage should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum levels are not expected to be appreciably affected by haemodialysis or peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Antibacterial for systemic use, macrolide</p><p><strong>ATC-Code:</strong> J01FA09</p><p>Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its antibacterial action by binding to the 50S ribosomal sub-unit of susceptible bacteria and suppresses protein synthesis. Clarithromycin demonstrates excellent&nbsp;<em>in vitro</em>activity against standard strains of clinical isolates. It is highly potent against a wide variety of aerobic and anaerobic gram-positive and gram-negative organisms. The minimum inhibitory concentrations (MICs) of clarithromycin are generally two-fold lower than the MICs of erythromycin.</p><p>The 14-(R)-hydroxy metabolite of clarithromycin, formed in man by first pass metabolism, also has antimicrobial activity. The MICs of this metabolite are equal to or two-fold higher than the MICs of the parent compound, except for&nbsp;<em>Haemophilus influenzae</em>&nbsp;where the 14-hydroxy metabolite is two-fold more active than the parent compound. Clarithromycin is also bactericidal against several bacterial strains.</p><p>Clarithromycin is usually active against the following organisms&nbsp;<em>in vitro</em>. Please see below for table of MIC breakpoints.</p><p>Gram-positive Bacteria:&nbsp;<em>Staphylococcus aureus</em>&nbsp;(methicillin susceptible)<em>; Streptococcus pyogenes&nbsp;</em>(Group A beta-hemolytic streptococci); alpha-hemolytic streptococci (viridans group)<em>; Streptococcus (Diplococcus) pneumoniae; Streptococcus agalactiae; Listeria monocytogenes.</em></p><p>Gram-negative Bacteria:&nbsp;<em>Haemophilus influenzae; Haemophilus parainfluenzae; Moraxella (Branhamella) catarrhalis; Neisseria gonorrhoeae; Legionella pneumophila; Bordetella pertussis; Helicobacter pylori; Campylobacter jejuni</em>.</p><p>Mycoplasma:&nbsp;<em>Mycoplasma pneumoniae; Ureaplasma urealyticum.</em></p><p>Other Organisms:&nbsp;<em>Chlamydia trachomatis; Mycobacterium avium; Mycobacterium leprae; Chlamydia pneumoniae</em>.</p><p>Anaerobes: Macrolide-susceptible&nbsp;<em>Bacteroides fragilis; Clostridium perfringens</em>;&nbsp;<em>Peptococcus</em>&nbsp;species;&nbsp;<em>Peptostreptococcus</em>species;&nbsp;<em>Propionibacterium acnes</em>.</p><p>Clarithromycin has bactericidal activity against several bacterial strains. The organisms include&nbsp;<em>Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus agalactiae, Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae, Helicobacter. pylori</em>&nbsp;and&nbsp;<em>Campylobacter</em>&nbsp;species.</p><p>The activity of clarithromycin against&nbsp;<em>H. pylori</em>&nbsp;is greater at neutral pH than at acid pH.</p><p><em>H. pylori</em>&nbsp;is associated with acid peptic disease including duodenal ulcer and gastric ulcer in which about 95% and 80% of patients respectively are infected with the agent.&nbsp;<em>H. pylori</em>&nbsp;is also implicated as a major contribution factor in the development of gastric and ulcer recurrence in such patients.</p><p>Clarithromycin has been used in small numbers of patients in other treatment regimens. Possible kinetic interactions have not been fully investigated. These regimens include:</p><p>Clarithromycin plus tinidazole and omeprazole; clarithromycin plus tetracycline, bismuth subsalicylate and ranitidine; clarithromycin plus ranitidine alone.</p><p>Clinical studies using various different&nbsp;<em>H. pylori</em>&nbsp;eradication regimens have shown that eradication of&nbsp;<em>H. pylori</em>&nbsp;prevents ulcer recurrence.</p><p><strong><em>Breakpoints</em></strong></p><p>The following breakpoints for clarithromycin, separating susceptible organisms from resistant organisms, have been established by the European Committee for Antimicrobial Susceptibility Testing (EUCAST).</p><table border="1" cellspacing="0" cellpadding="0" style="width:97%"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Breakpoints (MIC, &mu;g/ml)</p></td></tr><tr><td style="vertical-align:top"><p>Microorganism</p></td><td style="vertical-align:top"><p>Susceptible (&le;)</p></td><td style="vertical-align:top"><p>Resistant (&gt;)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>0.25 mcg/ml</p></td><td style="vertical-align:top"><p>0.5 mcg/ml</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>1 mcg/ml</p></td><td style="vertical-align:top"><p>2 mcg/ml</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>1 mcg/ml</p></td><td style="vertical-align:top"><p>32 mcg/ml</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>0.25 mcg/ml</p></td><td style="vertical-align:top"><p>0.5 mcg/ml</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Clarithromycin is used for the eradication of&nbsp;<em>H. pylori</em>; minimum inhibitory concentration (MIC) &le; 0.25 mcg/ml which has been established as the susceptible breakpoint by the Clinical and Laboratory Standards Institute (CLSI).</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>H. pylori&nbsp;</em>is associated with acid peptic disease including duodenal ulcer and gastric ulcer in which about 95% and 80% of patients respectively are infected with the agent.&nbsp;<em>H. pylori&nbsp;</em>is also implicated as a major contribution factor in the development of gastric and ulcer recurrence in such patients.</p><p>Clarithromycin has been used in small numbers of patients in other treatment regimens. Possible kinetic interactions have not been fully investigated. These regimens include:</p><p>Clarithromycin plus tinidazole and omeprazole; clarithromycin plus tetracycline, bismuth subsalicylate and ranitidine; clarithromycin plus ranitidine alone.</p><p>Clinical studies using various different&nbsp;<em>H. pylori&nbsp;</em>eradication regimens have shown that eradication of&nbsp;<em>H. pylori&nbsp;</em>prevents ulcer recurrence.</p><p>Clarithromycin is rapidly and well absorbed from the gastro-intestinal tract after oral administration of Clarithromycin tablets. The microbiologically active metabolite 14-hydroxyclarithromycin is formed by first pass metabolism. Clarithromycin may be given without regard to meals as food does not affect the extent of bioavailability of Clarithromycin tablets. Food does slightly delay the onset of absorption of clarithromycin and formation of the 14-hydroxymetabolite. The pharmacokinetics of clarithromycin are non linear; however, steady-state is attained within 2 days of dosing. At 250 mg b.i.d. 15-20% of unchanged drug is excreted in the urine. With 500 mg b.i.d. daily dosing urinary excretion is greater (approximately 36%). The 14-hydroxyclarithromycin is the major urinary metabolite and accounts for 10-15% of the dose. Most of the remainder of the dose is eliminated in the faeces, primarily via the bile. Five to 10% of the parent drug is recovered from the faeces.</p><p>When clarithromycin 500 mg is given three times daily, the clarithromycin plasma concentrations are increased with respect to the 500 mg twice daily dosage.</p><p>Clarithromycin provides tissue concentrations that are several times higher than the circulating drug levels. Increased levels have been found in both tonsillar and lung tissue. Clarithromycin is 80% bound to plasma proteins at therapeutic levels.</p><p>Clarithromycin also penetrates the gastric mucus. Levels of clarithromycin in gastric mucus and gastric tissue are higher when clarithromycin is co-administered with omeprazole than when clarithromycin is administered alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In acute mouse and rat studies, the median lethal dose was greater than the highest feasible dose for administration (5g/kg).</p><p>In repeated dose studies, toxicity was related to dose, duration of treatment and species. Dogs were more sensitive than primates or rats. The major clinical signs at toxic doses included emesis, weakness, reduced food consumption and weight gain, salivation, dehydration and hyperactivity.</p><p>In all species the liver was the primary target organ at toxic doses. Hepatotoxicity was detectable by early elevations of liver function tests. Discontinuation of the drug generally resulted in a return to or toward normal results. Other tissues less commonly affected included the stomach, thymus and other lymphoid tissues and the kidneys. At near therapeutic doses, conjunctival injection and lacrimation occurred only in dogs. At a massive dose of 400mg/kg/day, some dogs and monkeys developed corneal opacities and/or oedema.</p><p>Fertility and reproduction studies in rats have shown no adverse effects. Teratogenicity studies in rats (Wistar [p.o.] and Spraque-Dawley [p.o. and i.v.]), New Zealand White rabbits and cynomolgous monkeys failed to demonstrate any teratogenicity from clarithromycin. However, a further similar study in Sprague-Dawley rats indicated a low (6%) incidence of cardiovascular abnormalities which appeared to be due to spontaneous expression of genetic changes. Two mouse studies revealed a variable incidence (3-30%) of cleft palate and embryonic loss was seen in monkeys but only at dose levels which were clearly toxic to the mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:698px"><tbody><tr><td style="vertical-align:top"><p><strong><u>Inactive Ingredients:</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Croscarmellose Sodium (Ac-Di-Sol)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Polyvinyl Pyrrolidone K-30 (PVP K-30)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Pregelatinized Starch (Starch 1500)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Magnesium Stearate</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Colloidal Silicon Dioxide (Aerosil 200)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Talc Fine powder</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Polysorbate 80 (Tween 80)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Stearic Acid</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Microcrystalline Cellulose (Avicel PH 102)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Ethanol 95% *</li></ol></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Coating Materials:</u></strong></p></td></tr><tr><td style="vertical-align:top"><ol><li>Hypromellose (Hydroxypropyl MethylCellulose)</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Polyethylene Glycol 4000</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Titanium Dioxide</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Talc Fine Powder</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>D&amp;C Yellow No. 10 Lake</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Purified Water *</li></ol></td></tr><tr><td style="vertical-align:top"><ol><li>Ethanol 95% *</li></ol></td></tr></tbody></table><p>&nbsp;</p><p>* Evaporates during manufacturing process and does not appear in the final product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months from date of manufacturing.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.4 Special precautions for storage</p><p>Store below 30˚C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2 x 7&rsquo;s Tablets in blister strips, packed in a printed carton along with a leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates.
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04. July. 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>